Expect a commercial launch in the second half of fiscal year 2024.

Meet Venus Concept Inc.’s medical advisory board for AI.ME, its next generation robotic platform.

The primary mission of the medical advisory board will be to provide strategic input, guidance, and clinical recommendations regarding the Company's emerging robotic technology, AI.ME, which received its first 510(k) clearance from the U.S. Food and Drug Administration (FDA) in December 2022, for fractional skin resurfacing.

The medical advisory board is composed of:

• Glynis Ablon, MD, FAAD
• Macrene Alexiades, MD, PhD 
• Eric Bernstein, MD, MSE 
• James Chao, MD, FASC 
• Mitchel Goldman, MD 
• Gilly Munavalli MD, MHS, FACMS

AI.ME is the first and only robotic system cleared by FDA for fractional skin resurfacing. It uses machine vision and AI algorithms to target the skin. It conducts the treatment via a robotic arm using an array of rotating hollow punches, actuated via smart algorithm, to precisely core and excise micro skin-tissue fractions, triggering re-epithelization and collagen deposition.

"We are truly honored to convene this talented group of industry-leading physicians to form the AI.ME medical advisory board," says Dr. Hemanth Varghese, President, and Chief Innovation & Business Officer of Venus Concept, in a news release. " We believe that this group of experts is well positioned to guide us in realizing AI.ME's full clinical potential and ultimately helping us commercialize AI.ME in a way that transforms patient outcomes and physicians' approach to aesthetic procedures. We expect to begin engaging members of this group to start utilizing AI.ME in the clinical setting in the coming months.